Last reviewed · How we verify
BMS-914392
At a glance
| Generic name | BMS-914392 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden (PHASE2)
- Effect of Diltiazem on Pharmacokinetics of BMS-914392 (PHASE1)
- Effect of BMS-914392 on Pharmacokinetics of Metoprolol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-914392 CI brief — competitive landscape report
- BMS-914392 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI